Lilly’s Jaypirca shows positive results in phase 3 trial
Written by
PharmaTimes
Published
0
comments
0
min
Pirtobrutinib meets primary endpoint in CLL/SLL study Pirtobrutinib meets primary endpoint in CLL/SLL study